Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry.
Author
Barnes, Edward LDeepak, Parakkal
Beniwal-Patel, Poonam
Raffals, Laura
Kayal, Maia
Dubinsky, Marla
Chang, Shannon
Higgins, Peter D R
Barr, Jennifer I
Galanko, Joseph
Jiang, Yue
Cross, Raymond K
Long, Millie D
Herfarth, Hans H
Date
2022-08-02Journal
Crohn's & Colitis 360Publisher
Crohn’s & Colitis FoundationType
Article
Metadata
Show full item recordAbstract
Background. Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods. We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn’s disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results. We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P < .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment. Conclusions. In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.Rights/Terms
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.Identifier to cite or link to this item
http://hdl.handle.net/10713/19722ae974a485f413a2113503eed53cd6c53
10.1093/crocol/otac030
Scopus Count
Collections
Related articles
- A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis.
- Authors: Murrell ZA, Melmed GY, Ippoliti A, Vasiliauskas EA, Dubinsky M, Targan SR, Fleshner PR
- Issue date: 2009 May
- Transmural inflammation is not pathognomonic for Crohn's disease of the pouch.
- Authors: Liu ZX, Deroche T, Remzi FH, Hammel JP, Fazio VW, Ni RZ, Goldblum JR, Shen B
- Issue date: 2011 Nov
- A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis.
- Authors: White E, Melmed GY, Vasiliauskas EA, Dubinsky M, Berel D, Targan SR, Fleshner PR
- Issue date: 2010 Jul
- Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort.
- Authors: Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, Christophi G, Beniwal-Patel P, Isaacs KL, Raffals L, Deepak P, Herfarth HH, Barnes EL
- Issue date: 2019 Mar 14
- Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.
- Authors: Rocchi C, Soliman YY, Massidda M, Vadalà di Prampero SF, Bulajic M, Sorrentino D
- Issue date: 2022 Jun